- Home
- SLS vs INBX Comparison
SLS vs INBX Comparison
Compare SLS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | INBX |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SLS | INBX |
|---|---|---|
| Price | $8.50 | $90.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $32.50 | ★ $266.67 |
| AVG Volume (30 Days) | ★ 7.1M | 257.3K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $1.39 | $57.30 |
| 52 Week High | $15.88 | $155.29 |
Technical Indicators
Market Signals| Indicator | SLS | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 51.18 |
| Support Level | $4.09 | $85.14 |
| Resistance Level | $9.51 | $101.98 |
| Average True Range (ATR) | 0.98 | 7.88 |
| MACD | -0.17 | 1.55 |
| Stochastic Oscillator | 23.77 | 70.22 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.